SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced that...
SAN DIEGO, March 21, 2016 - Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most advanced internally developed site-specific...
SAN DIEGO, Nov. 16, 2015 Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex" Qiao. With nearly...
